Three Parents and a Baby - Scientists Advise Caution with Regard to Artificial Insemination Method
By Health Canal,
Health Canal
| 06. 18. 2014
The approval of a new treatment method by which three parents will be able to beget a child is being discussed since a few years in Great Britain and will possibly become a reality in two years. The method is supposed to help in eliminating the mother's genetic defects already in the test tube.
The defect lies in so-called mitochondria, the "power houses" of cells. To get rid of defective mitochondria the nucleus of one egg cell has to be transferred to another egg cell bearing intact mitochondria. Scientists at the Vetmeduni Vienna show for the first time that even a few defective mitochondria dragged along in the transfer could cause diseases. The results were published in Cell Reports.
Mitochondria are cell organelles located within animal and human cells. They produce energy for the organism, possess their own genetic material - mitochondrial DNA (mtDNA) - and are transmitted exclusively by the mother. Depending on their activity and tasks, different numbers of mitochondria are present in a cell - usually a few hundred to a thousand per body cell.
Inherited mitochondrial...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...